We are pleased to announce the appointment of Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated 18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.
Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.
The current year started well with a strong order book, increasing amounts of repeat business and a growing pipeline in biomarker services. With the level of SysQuant® /TMTcalibrator™ production doubled the increased capacity is being fully utilised at a time when the volume of customer enquiries is rising on a monthly basis and we are looking to further expand the sales team. Current indications point to a strong performance in 2016.
As global experts in mapping and analysis of protein changes in systems-wide biology, Proteome Sciences plc is strongly encouraged by two recent reports that emphasize the importance of protein profiling to improve outcomes in cancer treatment.
After closing 2015 with a good increase in revenues in the second half, the current year has started well with a strong order book and a growing pipeline in biomarker services.
The Company has received notification from Vulpes Life Sciences Fund (“Vulpes”) that it has a total direct and indirect interest in 36,573,125 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) equivalent to 16.04% of Proteome Sciences’ total issued share capital.
From the 8th Clinical Trials on Alzheimer’s Disease in Barcelona, PS announces that a recently completed study testing its proprietary inhibitors of CK1d reduced the level of tau phosphorylation in a second in vivo model of Alzheimer’s disease tauopathy.